Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 11/20 | 0.55 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.55 |
| ▸ | ACVR1 | Q04771 | 4/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | KDM4A | O75164 | 1/20 | 0.46 |
| ▸ | KDM4B | O94953 | 1/20 | 0.46 |
| ▸ | KDM5C | P41229 | 1/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.46 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.46 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL30083057 | 0.86 | L3MBTL1 (0.44) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| SCHEMBL31038815 | 0.76 | PSMD14 (0.43) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| SCHEMBL5139409 | 0.74 | KDM4A (0.44) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| SCHEMBL192176 | 0.73 | KDM4E (0.41) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| Quinazolinone SCHEMBL27983253 | 0.71 | PARP1 (1.00) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| Quinazolinone SCHEMBL88525 | 0.71 | PARP1 (1.00) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| SCHEMBL26038410 | 0.71 | MAPK1 (0.50) | PARP1ALDH1A1KDM4EJAK2 | |
| SCHEMBL4681318 | 0.71 | PARP1 (0.40) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| SCHEMBL10637102 | 0.71 | PARP1 (0.53) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| SCHEMBL10759 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 302 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117136060-A | Methods of treating inflammatory diseases | 里邦医疗公司 | 2023-11-28 | — | — | CN | claimed |
| EP-3728207-B1 | QUINAZOLINONES AS PARP14 INHIBITORS | RIBON THERAPEUTICS INC (US) | 2023-02-01 | — | — | EP | claimed |
| CN-114222737-A | Small molecule inhibitor of NF-kB induced kinase | 詹森药业有限公司 | 2022-03-22 | — | — | CN | claimed |
| US-10858335-B2 | 2,3-Disubstituted pyridine compounds as TGF-β inhibitors and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2020-12-08 | — | — | US | claimed |
| US-20190284155-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | RIGEL PHARMACEUTICALS, INC. (US) | 2019-09-19 | — | — | US | claimed |
| US-10233170-B2 | 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2019-03-19 | — | — | US | claimed |
| US-20170096409-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | MIDCAP FINANCIAL TRUST | 2017-04-06 | — | — | US | claimed |
| EP-3129367-A1 | 2,3-DISUBSTITUTED PYRIDINE COMPOUNDS AS TGF-BETA INHIBITORS AND METHODS OF USE | Rigel Pharmaceuticals, Inc. (US) | 2017-02-15 | — | — | EP | claimed |
| WO-2015157093-A1 | 2,3-DISUBSTITUTED PYRIDINE COMPOUNDS AS TGF-BETA INHIBITORS AND METHODS OF USE | RIGEL PHARMACEUTICALS, INC. (US) | 2015-10-15 | — | — | WO | claimed |
| US-7169926-B1 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-30 | — | — | US | claimed |
| US-20040242568-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2004-12-02 | — | — | US | claimed |
| WO-2004087053-A9 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX INC (US) | 2004-11-11 | — | — | WO | claimed |
| WO-2004087053-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX, INC. (US) | 2004-10-14 | — | — | WO | claimed |
| US-20040167095-A1 | Use of PDE V inhibitors for improved fecundity in mammals | WESTBROOK SIMON LEMPRIERE (GB) | 2004-08-26 | — | — | US | claimed |
| EP-1365806-A2 | USE OF NO ACTTIVATORS FOR TREATMENT AND PREVENTION OF GASTROINTESTINAL DISORDERS | JOHNS HOPKINS UNIVERSITY (US) | 2003-12-03 | — | — | EP | claimed |
| US-20020128171-A1 | Methods for prevention and treatment of gastrointestinal disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-09-12 | — | — | US | claimed |
| WO-2001078781-A9 | METHODS FOR PREVENTION AND TREATMENT OF GASTROINTESTINAL DISORDERS | UNIV JOHNS HOPKINS (US) | 2002-07-25 | — | — | WO | claimed |
| WO-2001078781-A2 | METHODS FOR PREVENTION AND TREATMENT OF GASTROINTESTINAL DISORDERS | JOHNS HOPKINS UNIVERSITY (US) | 2001-10-25 | — | — | WO | claimed |
| EP-0733633-A1 | Heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-09-25 | — | — | EP | claimed |
| EP-0537937-A2 | Substituted pyrazino 2,3-D pyrimidinones as angiotensin II antagonists | MERCK & CO. INC. (US) | 1993-04-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167095-A1 | Use of PDE V inhibitors for improved fecundity in mammals | PDE5A, PDE2A, PDE3A | PARP1 574/4885PDPK1 165/4885CA12 4793/4885 |
| US-20020128171-A1 | Methods for prevention and treatment of gastrointestinal disorders | VIP, GIPR, IAPP | PARP1 2937/4885PDPK1 1508/4885CA12 1646/4885 |
| US-10233170-B2 | 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use | TGFBR1, TGFBR2, ACVR1 | PARP1 1816/4885PDPK1 948/4885CA12 1074/4885 |
| US-20040242568-A1 | Dipeptidyl peptidase inhibitors | DPP9, DPP4, DPP3 | PARP1 1840/4885PDPK1 2094/4885CA12 352/4885 |
| US-10858335-B2 | 2,3-Disubstituted pyridine compounds as TGF-β inhibitors and methods of use | SMAD3, TGFBR1, TGFBR2 | PARP1 1184/4885PDPK1 741/4885CA12 1559/4885 |
| US-20190284155-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | TGFBR2, ACVR1, TGFBR1 | PARP1 1180/4885PDPK1 928/4885CA12 1393/4885 |
| US-20170096409-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | TGFBR1, TGFBR2, ACVR1 | PARP1 1816/4885PDPK1 948/4885CA12 1074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.